Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stake Boosted by Koshinski Asset Management Inc.

Koshinski Asset Management Inc. increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,357 shares of the pharmaceutical company’s stock after purchasing an additional 45 shares during the period. Koshinski Asset Management Inc.’s holdings in Vertex Pharmaceuticals were worth $546,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Northwest Investment Counselors LLC acquired a new stake in Vertex Pharmaceuticals in the third quarter worth $25,000. Dunhill Financial LLC increased its position in Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares during the period. Highline Wealth Partners LLC acquired a new stake in Vertex Pharmaceuticals in the third quarter worth $27,000. Legacy Investment Solutions LLC acquired a new stake in Vertex Pharmaceuticals in the third quarter worth $33,000. Finally, Truvestments Capital LLC acquired a new stake in Vertex Pharmaceuticals in the third quarter worth $35,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Barclays dropped their target price on Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating on the stock in a research report on Friday, December 20th. Scotiabank raised their price target on Vertex Pharmaceuticals from $426.00 to $430.00 and gave the company a “sector perform” rating in a report on Monday, December 23rd. Jefferies Financial Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price target for the company from $500.00 to $550.00 in a report on Monday, December 9th. JPMorgan Chase & Co. lowered their price target on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating on the stock in a report on Monday, December 23rd. Finally, UBS Group raised their price target on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $490.38.

Vertex Pharmaceuticals Trading Up 0.0 %

NASDAQ:VRTX opened at $428.00 on Thursday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The firm has a market capitalization of $110.22 billion, a price-to-earnings ratio of -215.08, a price-to-earnings-growth ratio of 2.17 and a beta of 0.40. The stock has a fifty day simple moving average of $438.10 and a 200 day simple moving average of $465.39.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same period last year, the company posted $3.67 EPS. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. Sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.